Recent Updates
Recently added Catalysts

RHB-105

Phase 3

Helicobacter Pylori Infection | Small molecule | Other |Redhill Biopharma Ltd.|Last Updated: Mar 16, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment455
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03198507ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active ComparatorPHASE3 COMPLETED 455Jun 18, 2017Dec 13, 2018Mar 16, 202055 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Eradication of H. Pylori
43-71 days after initiation of treatment

Eradication of H. pylori confirmed via 13C Urea Breath Test (UBT) testing. Subjects with negative test results (eradication of H. pylori) were considered treatment successes. Subjects who tested positive for H. pylori infection (no eradication) were considered treatment failures.

Secondary Endpoints
Number of Participants With H. Pylori Cultures That Presented Antibiotic Resistance and Susceptibility
43-71 days after initiation of treatment
Number of Participants With Adverse Events That Are Related to Treatment
After first dose of study drug until 28 days following last dose.
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
RHB-105EXPERIMENTALRHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin
Active ComparatorACTIVE_COMPARATORActive comparator is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin and Omeprazole; as well as separate Riboflavin
Interventions
NameTypeDescription
RHB-105DRUGThe intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of: * Rifabutin 150 mg * Amoxicillin 3000 mg * Omeprazole 120 mg One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Active ComparatorDRUGThe intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of: * Amoxicillin 3000 mg * Omeprazole 120 mg One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites55

Inclusion Criteria: 1. Be ages 18 - 70, inclusive; non-Asian males and females (This population has been demonstrated to have significantly elevated omeprazole levels as per the prescriber information for other omeprazole products). A person having origins in any of the original peoples of the Far ...

Countries:United States
Unlock Eligibility Criteria